Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.44 |
| ▸ | PDE4A | P27815 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5058864 | 0.91 | PDE4D (0.38) | PDE4DPDE4APDE4BPDE4CKMT2A | |
| SCHEMBL5058905 | 0.91 | PDE4D (0.49) | PDE4DPDE4APDE4BPDE4CKMT2A | |
| SCHEMBL6387528 | 0.87 | PDE4D (0.47) | PDE4DPDE4APDE4BPDE4CKMT2A | |
| SCHEMBL5478908 | 0.86 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CKMT2A | |
| SCHEMBL5066761 | 0.84 | PDE4D (0.45) | PDE4DPDE4APDE4BPDE4CKMT2A | |
| SCHEMBL2264819 | 0.82 | PDE4A (0.46) | PDE4DPDE4APDE4BPDE4CFPR2 | |
| SCHEMBL2265927 | 0.82 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4CKMT2A | |
| SCHEMBL2270164 | 0.82 | PDE4D (0.47) | PDE4DPDE4APDE4BPDE4CKMT2A | |
| SCHEMBL6389244 | 0.81 | PDE4D (0.49) | PDE4DPDE4APDE4BPDE4CKMT2A | |
| SCHEMBL6390285 | 0.81 | PDE4D (0.52) | PDE4DPDE4APDE4BPDE4CKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161339-A1 | Novel Thio-Containing Hydroxy-6-Phenylphenanthridines and their Use as Pde4 Inhibitors | ALTANA PHARMA AG (DE) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161339-A1 | Novel Thio-Containing Hydroxy-6-Phenylphenanthridines and their Use as Pde4 Inhibitors | PDE4A, PDE4B, PDE4C | PDE4D 4/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.